Expresión inmunohistoquímica de p53, p21, p16 y Ciclina D1 en el cáncer de vejiga superficial. Estudio en un soporte de tissue microarray

Llena, F.R. Vallmanya; Rodríguez, Adelaida; Trull, Josep Lloreta; Ángel, R. Cortadellas; Santos, J. Placer; Mas, A. Gelabert

doi:10.1016/s0210-4806(06)73532-x

Cited by 16 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the expression of p16 INK4A has been statistically associated with disease stage but not with either tumor grade or disease progression [31]. p16 INK4A expression has also been related to recurrence and survival [34]. In the present study, the mRNA levels of p16 INK4A were higher in BC vs. normal tissue, as assessed by qPCR.…”

Section: Discussionmentioning

confidence: 47%

Spotlight on Differentially Expressed Genes in Urinary Bladder Cancer

et al. 2011

View full text Add to dashboard Cite

IntroductionWe previously identified common differentially expressed (DE) genes in bladder cancer (BC). In the present study we analyzed in depth, the expression of several groups of these DE genes.Materials and MethodsSamples from 30 human BCs and their adjacent normal tissues were analyzed by whole genome cDNA microarrays, qRT-PCR and Western blotting. Our attention was focused on cell-cycle control and DNA damage repair genes, genes related to apoptosis, signal transduction, angiogenesis, as well as cellular proliferation, invasion and metastasis. Four publicly available GEO Datasets were further analyzed, and the expression data of the genes of interest (GOIs) were compared to those of the present study. The relationship among the GOI was also investigated. GO and KEGG molecular pathway analysis was performed to identify possible enrichment of genes with specific biological themes.ResultsUnsupervised cluster analysis of DNA microarray data revealed a clear distinction in BC vs. control samples and low vs. high grade tumors. Genes with at least 2-fold differential expression in BC vs. controls, as well as in non-muscle invasive vs. muscle invasive tumors and in low vs. high grade tumors, were identified and ranked. Specific attention was paid to the changes in osteopontin (OPN, SPP1) expression, due to its multiple biological functions. Similarly, genes exhibiting equal or low expression in BC vs. the controls were scored. Significant pair-wise correlations in gene expression were scored. GO analysis revealed the multi-facet character of the GOIs, since they participate in a variety of mechanisms, including cell proliferation, cell death, metabolism, cell shape, and cytoskeletal re-organization. KEGG analysis revealed that the most significant pathway was that of Bladder Cancer (p = 1.5×10−31).ConclusionsThe present work adds to the current knowledge on molecular signature identification of BC. Such works should progress in order to gain more insight into disease molecular mechanisms.

show abstract

Section: Discussionmentioning

confidence: 47%

Spotlight on Differentially Expressed Genes in Urinary Bladder Cancer

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The full text of the remaining 142 articles was then reviewed for their fit with the current study, after which a further 105 articles were excluded because they met one or more of the exclusion criteria, such as the cell or animal studies, reviews, and letters and studies with identical data and no extractable HR, OR, and 95% CI data from the full text or language barrier. The remaining 37 articles [ 4 , 5 , 8 – 42 ] with 2246 cases were included in our study and consisted of 21 English [ 4 , 5 , 8 – 19 , 21 – 25 , 41 , 42 ] and 16 Chinese [ 20 , 26 – 40 ] articles. The screening process was demonstrated in Figure 2 .…”

Section: Resultsmentioning

confidence: 99%

“…The basic features of the included studies were presented in Table 1 . Among the 37 articles, 26 studies [ 4 , 5 , 8 – 21 , 28 – 34 , 39 , 41 , 42 ] investigated the relationship between low expression of p16 and prognostic parameters in bladder cancer patients (RFS, OS, PFS, and DSS/CSS), and 30 studies [ 4 , 10 – 13 , 15 – 19 , 21 – 40 ] assessed the association between p16 and clinicopathological factors in patients with bladder cancer.…”

Section: Resultsmentioning

confidence: 99%

“…A total of 17 studies with 1032 subjects were included in the final analysis of RFS [ 4 , 5 , 8 , 10 , 13 – 15 , 19 , 21 , 28 – 34 , 39 ]. Low expression of p16 was related to poor RFS in patients with bladder cancer (HR = 1.63, 95% CI = 1.36~1.94, and P < 0.001), with low observed heterogeneity ( I 2 = 42.6%, P = 0.029) ( Figure 3(a) ).…”

Section: Resultsmentioning

confidence: 99%

“…A total of 425 subjects in eight studies were included in the final analysis of OS [ 9 , 11 , 14 , 16 , 19 , 20 , 30 , 34 ], which showed that low expression of p16 was associated with decreased OS in patients with bladder cancer (HR = 1.70, 95% CI = 1.16~2.50, and P = 0.007), with no significant observed heterogeneity ( I 2 = 0%, P = 0.584) ( Figure 3(b) ).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis

Gan

Lin

et al. 2016

Disease Markers

View full text Add to dashboard Cite

p16, encoded by the CDKN2A gene, is a tumor suppressor that has been widely studied in cancer research. However, the relationship of p16 with prognostic and clinicopathological parameters in patients with bladder cancer remains unclear. Data inclusion criteria were articles reporting on the relationship between p16 expression and the prognosis or clinicopathology in patients with bladder cancer. Meta-analyses were performed with Stata software. Hazard ratios (HRs) or odds ratios (ORs) and 95% confidence intervals (95% CI) were calculated to evaluate the relative risks. The source of heterogeneity was analyzed by subgroup analysis. A total of 37 studies with 2246 cases were included and analyzed. The results identified an important link between downregulated p16 expression and poor prognosis in patients with bladder cancer in terms of recurrence-free survival (RFS), overall survival (OS), progression-free survival (PFS), and some clinicopathological parameters including clinical staging, pathological degree, and lymph node metastasis. Subgroup analysis also showed that low p16 expression could function as a warning sign for RFS and PFS in patients with early-stage (Ta–T1) bladder cancer. In conclusion, p16 might play an essential role in the deterioration of bladder cancer and could serve as a biomarker for the prediction for patients' progression and prognosis.

show abstract

Value of p16^INK4a in the diagnosis of low‐grade urothelial carcinoma of the urinary bladder in urinary cytology

Alameda

Juanpere²,

Pijuán³

et al. 2012

Cancer Cytopathology

View full text Add to dashboard Cite

show abstract

Expresión inmunohistoquímica de p53, p21, p16 y Ciclina D1 en el cáncer de vejiga superficial. Estudio en un soporte de tissue microarray

Abstract: In our experience, only p16 and p21 may be useful in the management of superficial bladder tumors, as they are predictors of recurrence and survival in Ta and T1 patients.

Cited by 16 publications

References 24 publications

Spotlight on Differentially Expressed Genes in Urinary Bladder Cancer

Spotlight on Differentially Expressed Genes in Urinary Bladder Cancer

Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis

Value of p16^INK4a in the diagnosis of low‐grade urothelial carcinoma of the urinary bladder in urinary cytology

Contact Info

Product

Resources

About

Expresión inmunohistoquímica de p53, p21, p16 y Ciclina D1 en el cáncer de vejiga superficial. Estudio en un soporte de tissue microarray

Abstract: In our experience, only p16 and p21 may be useful in the management of superficial bladder tumors, as they are predictors of recurrence and survival in Ta and T1 patients.

Cited by 16 publications

References 24 publications

Spotlight on Differentially Expressed Genes in Urinary Bladder Cancer

Spotlight on Differentially Expressed Genes in Urinary Bladder Cancer

Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis

Value of p16INK4a in the diagnosis of low‐grade urothelial carcinoma of the urinary bladder in urinary cytology

Contact Info

Product

Resources

About

Value of p16^INK4a in the diagnosis of low‐grade urothelial carcinoma of the urinary bladder in urinary cytology